title: The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions.
abstract: Food allergy is a potentially life-threatening disease which affects up to 8% of children and 2-3% of adults. Increasing food allergy prevalence poses a major public health concern. Induction of desensitization to food allergens through oral immunotherapy (OIT) is an expanding area of study encompassing peanut, egg, milk, and other food allergens. OIT consists of administering incremental doses of food allergen to food-allergic patients, to induce a state of desensitization. Safety, tolerability, and efficacy all remain ongoing concerns. Clinical trials for oral immunotherapy have encompassed many variations, including differences in dosage sizes and frequency, duration of build-up, type of allergen used, patient characteristics, and adjuvant therapies. Consequently, studies have also shown variation in rates of adverse effects, and successful desensitization. Here, we provide an overview of the key studies and discuss the implications of this heterogeneity. While desensitization is successful in the majority of patients, only a minority appear to develop sustained unresponsiveness even after years of therapy. Much larger and longitudinal studies using more homogenous protocols are needed in order to evaluate the clinical applicability of OIT, its long-term effectiveness, and effect on quality of life. The role of adjunctive therapies, including omalizumab and probiotics, requires further evaluation.
authors.affiliation: Division of Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
authors.forename: Christina S K
authors.initials: CS
authors.lastname: Yee
authors.affiliation: Division of Allergy and Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Rima.Rachid@childrens.harvard.edu.
authors.forename: Rima
authors.initials: R
authors.lastname: Rachid
mesh_terms: D000284:Administration, Oral; D000485:Allergens / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic / Q000379:methods* / Q000639:trends; D005512:Food Hypersensitivity / Q000628:therapy*; D006801:Humans; D000069444:Omalizumab
chemical_list: D000485:Allergens; D000069444:Omalizumab
keywords: Desensitization; Food allergy; Oral immunotherapy; Sustained unresponsiveness